JP2018522927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522927A5 JP2018522927A5 JP2018507010A JP2018507010A JP2018522927A5 JP 2018522927 A5 JP2018522927 A5 JP 2018522927A5 JP 2018507010 A JP2018507010 A JP 2018507010A JP 2018507010 A JP2018507010 A JP 2018507010A JP 2018522927 A5 JP2018522927 A5 JP 2018522927A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- inhibitors
- hiv
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 125000001475 halogen functional group Chemical group 0.000 claims description 20
- -1 phenoxy, benzyloxy, carboxy, phenyl Chemical group 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 3
- 230000034303 cell budding Effects 0.000 claims description 3
- 239000002835 hiv fusion inhibitor Substances 0.000 claims description 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 description 17
- 125000004438 haloalkoxy group Chemical group 0.000 description 12
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 5
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 5
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203791P | 2015-08-11 | 2015-08-11 | |
| US62/203,791 | 2015-08-11 | ||
| PCT/IB2016/054832 WO2017025917A1 (en) | 2015-08-11 | 2016-08-10 | 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522927A JP2018522927A (ja) | 2018-08-16 |
| JP2018522927A5 true JP2018522927A5 (cg-RX-API-DMAC7.html) | 2018-09-27 |
| JP6782766B2 JP6782766B2 (ja) | 2020-11-11 |
Family
ID=56851651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507010A Active JP6782766B2 (ja) | 2015-08-11 | 2016-08-10 | ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体 |
Country Status (23)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201718537A (zh) * | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| US10577353B2 (en) * | 2015-08-12 | 2020-03-03 | VIIV Healthcare UK (No.5) Limited | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455217A1 (en) * | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455214A1 (en) * | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017195113A1 (en) * | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20200016136A1 (en) * | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TW201835068A (zh) * | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| HRP20120328T2 (hr) | 2007-11-15 | 2012-09-30 | Gilead Sciences | Inhibitori replikacije virusa humane imunodeficijencije |
| EP2574610A1 (en) | 2007-11-15 | 2013-04-03 | Gilead Sciences, Inc. | Inhibitors of human immonodeficiency virus replication |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| CA2705338A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2781780C (en) | 2009-12-23 | 2015-02-17 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9580431B2 (en) | 2013-03-13 | 2017-02-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP2970274B1 (en) | 2013-03-14 | 2017-03-01 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US9637501B2 (en) | 2014-02-20 | 2017-05-02 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication |
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US10577353B2 (en) * | 2015-08-12 | 2020-03-03 | VIIV Healthcare UK (No.5) Limited | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| AU2016305339A1 (en) * | 2015-08-12 | 2018-03-01 | VIIV Healthcare UK (No.5) Limited | 5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication |
| TW201718537A (zh) * | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
-
2016
- 2016-08-09 AR ARP160102438A patent/AR105653A1/es unknown
- 2016-08-09 TW TW105125345A patent/TWI657086B/zh not_active IP Right Cessation
- 2016-08-10 EP EP16758283.2A patent/EP3334716A1/en not_active Withdrawn
- 2016-08-10 MA MA042614A patent/MA42614A/fr unknown
- 2016-08-10 PE PE2018000174A patent/PE20181002A1/es unknown
- 2016-08-10 CN CN201680059469.XA patent/CN108137534A/zh active Pending
- 2016-08-10 KR KR1020187006791A patent/KR20180032649A/ko not_active Withdrawn
- 2016-08-10 US US15/749,176 patent/US10189816B2/en active Active
- 2016-08-10 CA CA2994791A patent/CA2994791A1/en not_active Abandoned
- 2016-08-10 HK HK18108030.5A patent/HK1249503A1/zh unknown
- 2016-08-10 AU AU2016306089A patent/AU2016306089B2/en not_active Ceased
- 2016-08-10 CR CR20180091A patent/CR20180091A/es unknown
- 2016-08-10 WO PCT/IB2016/054832 patent/WO2017025917A1/en not_active Ceased
- 2016-08-10 MX MX2018001722A patent/MX2018001722A/es unknown
- 2016-08-10 EA EA201890361A patent/EA033057B1/ru not_active IP Right Cessation
- 2016-08-10 JP JP2018507010A patent/JP6782766B2/ja active Active
- 2016-08-10 UA UAA201801137A patent/UA120464C2/uk unknown
-
2018
- 2018-01-30 IL IL257240A patent/IL257240B/en not_active IP Right Cessation
- 2018-02-01 ZA ZA2018/00689A patent/ZA201800689B/en unknown
- 2018-02-06 DO DO2018000035A patent/DOP2018000035A/es unknown
- 2018-02-08 CL CL2018000363A patent/CL2018000363A1/es unknown
- 2018-02-09 CO CONC2018/0001359A patent/CO2018001359A2/es unknown
- 2018-02-09 PH PH12018500294A patent/PH12018500294A1/en unknown
- 2018-11-28 US US16/202,653 patent/US20190092754A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522927A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524841A5 (cg-RX-API-DMAC7.html) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| PH12021550931A1 (en) | New anthelmintic compounds | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| JP2016525102A5 (cg-RX-API-DMAC7.html) | ||
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| JP2017526748A5 (cg-RX-API-DMAC7.html) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2016512558A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512507A5 (cg-RX-API-DMAC7.html) | ||
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2018090566A5 (cg-RX-API-DMAC7.html) | ||
| RU2018106504A (ru) | Производные пиридин 3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| JP2016516692A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509050A5 (cg-RX-API-DMAC7.html) | ||
| MX2024002409A (es) | Terapias contra el cancer. | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| JP2014148552A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512501A5 (cg-RX-API-DMAC7.html) |